PARP1 and small cell lung carcinoma: As proteomic analysis revealed an inverse correlation between activity of the PI3K/mTOR pathway and response to talazoparib in vitro [5], we hypothesized that the addition of PI3K/mTOR inhibition might further sensitize SCLC to PARP inhibitors.